pirenzepine has been researched along with Basal Ganglia Diseases in 56 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities." | 9.11 | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. ( Banki, CM; Bartko, G; Bitter, I; Breier, A; Brook, S; Dossenbach, MR; Feldman, PD; Füredi, J; Gagiano, CA; Janka, Z; Kovacs, G; Metcalfe, S, 2004) |
| "Our results indicate that in patients with treatment-resistant schizophrenia, a switch to olanzapine after treatment failure with an atypical agent or haloperidol may not reduce psychopathology in general, but may improve symptoms related to cognitive function." | 9.10 | Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "Twenty patients who had previously received treatment with typical antipsychotic agents and who met the DSM-IV criteria of schizophrenia and refractoriness to treatment were evaluated in a 1-year prospective study after switching to olanzapine." | 9.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| "Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7." | 9.10 | Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003) |
| "Twenty female patients with DSM-IV schizophrenia who were taking risperidone and were suffering from menstrual disturbances, galactorrhea, and/or sexual dysfunction were enrolled." | 9.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "This study evaluated the effectiveness, safety, and quality of life (Qol) offered by olanzapine in first-episode schizophrenia." | 9.10 | Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. ( Ciudad, A; Gascón, J; Gómez, JC; Montes, JM, 2003) |
| "Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine." | 9.09 | Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. ( Gonzalez, V; Kopelowicz, A; Mintz, J; Tripodis, K; Zarate, R, 2000) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 9.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "One hundred three previously treatment-resistant patients with schizophrenia diagnosed according to the DSM-III-R criteria were given a prospective 6-week trial of 10-40 mg/day of haloperidol." | 9.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 8.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| "The role of olanzapine in treatment-resistant schizophrenia is still unresolved." | 7.71 | Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. ( Chakos, M; Citrome, L; Czobor, P; Iskander, A; Lieberman, J; Lindenmayer, JP; Parker, B; Sheitman, B; Volavka, J, 2001) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 7.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| " Safety was evaluated through the collection of spontaneous adverse events and a specific questionnaire for extrapyramidal symptoms." | 6.69 | The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. ( Antón Saiz, C; Breier, A; Fontova Carbonell, E; Gómez, JC; Hernández, J; Ruiz Carrasco, P; Sacristán, JA, 2000) |
| "Olanzapine has been reported as less likely to cause EPS and may improve some negative signs." | 6.69 | The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998) |
| "Olanzapine is a new antipsychotic drug that has shown efficacy against positive and negative symptoms of schizophrenia, with minimal extrapyramidal side effects." | 6.68 | Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. ( Alvarez, E; Cuesta, M; García-Bernardo, E; Gómez, JC; Gurpegui, M; Martín, J, 1997) |
| "Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities." | 5.11 | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. ( Banki, CM; Bartko, G; Bitter, I; Breier, A; Brook, S; Dossenbach, MR; Feldman, PD; Füredi, J; Gagiano, CA; Janka, Z; Kovacs, G; Metcalfe, S, 2004) |
| "This study evaluated the effectiveness, safety, and quality of life (Qol) offered by olanzapine in first-episode schizophrenia." | 5.10 | Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. ( Ciudad, A; Gascón, J; Gómez, JC; Montes, JM, 2003) |
| "Our results indicate that in patients with treatment-resistant schizophrenia, a switch to olanzapine after treatment failure with an atypical agent or haloperidol may not reduce psychopathology in general, but may improve symptoms related to cognitive function." | 5.10 | Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "Twenty patients who had previously received treatment with typical antipsychotic agents and who met the DSM-IV criteria of schizophrenia and refractoriness to treatment were evaluated in a 1-year prospective study after switching to olanzapine." | 5.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| "The superiority of olanzapine to haloperidol with respect to a decreased incidence of treatment-emergent extrapyramidal syndromes (EPS) in patients with schizophrenia was demonstrated in studies conducted in both Japan and Western countries." | 5.10 | Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. ( Beasley, CM; Inada, T; Tanaka, Y; Walker, DJ, 2003) |
| "Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7." | 5.10 | Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003) |
| "Twenty female patients with DSM-IV schizophrenia who were taking risperidone and were suffering from menstrual disturbances, galactorrhea, and/or sexual dysfunction were enrolled." | 5.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine." | 5.09 | Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. ( Gonzalez, V; Kopelowicz, A; Mintz, J; Tripodis, K; Zarate, R, 2000) |
| "This open-label clinical study was conducted for patients with schizophrenia in order to investigate the efficacy, safety and optimal dose of olanzapine." | 5.09 | Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group. ( Ishigooka, J; Miura, S; Murasaki, M, 2000) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 5.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "One hundred three previously treatment-resistant patients with schizophrenia diagnosed according to the DSM-III-R criteria were given a prospective 6-week trial of 10-40 mg/day of haloperidol." | 5.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 4.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics." | 4.80 | Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. ( Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G, 1999) |
| " Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol." | 4.79 | Dosing the antipsychotic medication olanzapine. ( Nemeroff, CB, 1997) |
| "The role of olanzapine in treatment-resistant schizophrenia is still unresolved." | 3.71 | Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. ( Chakos, M; Citrome, L; Czobor, P; Iskander, A; Lieberman, J; Lindenmayer, JP; Parker, B; Sheitman, B; Volavka, J, 2001) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 3.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| "The objectives of this study were to determine the doses of olanzapine (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in outpatients with schizophrenia and the rates of occurrence of extrapyramidal symptoms (EPS) and other adverse events, clinical response, and use of concomitant medications." | 3.70 | Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. ( Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E, 2000) |
| " Although the nature of adverse events differed between the two agents, retention in the study was greater with olanzapine." | 2.71 | Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. ( Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R, 2003) |
| "Olanzapine is a novel atypical antipsychotic drug with few reported extrapyramidal side effects which may be more suitable for controlling hallucinosis in these patients." | 2.69 | Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. ( Ford, KS; Graham, JM; Sagar, HJ; Sussman, JD, 1998) |
| "Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients." | 2.69 | Olanzapine versus haloperidol treatment in first-episode psychosis. ( Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD, 1999) |
| "Olanzapine has been reported as less likely to cause EPS and may improve some negative signs." | 2.69 | The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998) |
| " Safety was evaluated through the collection of spontaneous adverse events and a specific questionnaire for extrapyramidal symptoms." | 2.69 | The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. ( Antón Saiz, C; Breier, A; Fontova Carbonell, E; Gómez, JC; Hernández, J; Ruiz Carrasco, P; Sacristán, JA, 2000) |
| " The D2 receptor availability revealed an exponential dose-response relationship (r = - 0." | 2.69 | D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. ( Dresel, S; Frodl, T; Hahn, K; Mager, T; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K, 2000) |
| "Olanzapine is a new antipsychotic drug that has shown efficacy against positive and negative symptoms of schizophrenia, with minimal extrapyramidal side effects." | 2.68 | Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. ( Alvarez, E; Cuesta, M; García-Bernardo, E; Gómez, JC; Gurpegui, M; Martín, J, 1997) |
| "Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity." | 2.42 | Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. ( Potvin, S; Roy, JY; Stip, E, 2003) |
| "Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects." | 2.40 | The relationship of pharmacology to side effects. ( Casey, DE, 1997) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| " Relatively little information on adverse events (AEs), specifically in children or adolescents taking atypical antipsychotics, is available." | 1.31 | Effects of development on olanzapine-associated adverse events. ( Martin, A; McGlashan, TH; Spector, SG; Woods, SW, 2002) |
| "Olanzapine is a new atypical antipsychotic agent that belongs to the same chemical class as clozapine." | 1.30 | In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. ( Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (35.71) | 18.2507 |
| 2000's | 36 (64.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inada, T | 2 |
| Yagi, G | 1 |
| Miura, S | 2 |
| Lindenmayer, JP | 3 |
| Czobor, P | 2 |
| Volavka, J | 2 |
| Lieberman, JA | 3 |
| Citrome, L | 2 |
| Sheitman, B | 2 |
| Chakos, M | 2 |
| McEvoy, JP | 1 |
| Woods, SW | 1 |
| Martin, A | 1 |
| Spector, SG | 1 |
| McGlashan, TH | 1 |
| Rodríguez-Pérez, V | 1 |
| López, A | 3 |
| Blanco, C | 1 |
| Peña, C | 1 |
| Abel, A | 1 |
| Gómez, Y | 1 |
| Ferreiro, MJ | 1 |
| Rego, C | 1 |
| Cudeiro, F | 1 |
| Alvarez, V | 1 |
| Prieto, R | 1 |
| Ciudad, A | 2 |
| Beasley, CM | 4 |
| Tanaka, Y | 1 |
| Walker, DJ | 1 |
| de Haan, L | 2 |
| van Bruggen, M | 1 |
| Lavalaye, J | 2 |
| Booij, J | 2 |
| Dingemans, PM | 2 |
| Linszen, D | 2 |
| Meibach, RC | 1 |
| Potvin, S | 1 |
| Stip, E | 1 |
| Roy, JY | 1 |
| Lambert, TJ | 1 |
| Castle, DJ | 1 |
| Montes, JM | 1 |
| Gascón, J | 1 |
| Gómez, JC | 4 |
| Tollefson, G | 1 |
| Tohen, M | 3 |
| Green, AI | 1 |
| Gur, RE | 1 |
| Kahn, R | 1 |
| McEvoy, J | 1 |
| Perkins, D | 1 |
| Sharma, T | 1 |
| Zipursky, R | 1 |
| Wei, H | 2 |
| Hamer, RM | 1 |
| Carlson, CD | 1 |
| Cavazzoni, PA | 1 |
| Berg, PH | 1 |
| Kane, JM | 1 |
| Bitter, I | 1 |
| Dossenbach, MR | 1 |
| Brook, S | 1 |
| Feldman, PD | 2 |
| Metcalfe, S | 1 |
| Gagiano, CA | 1 |
| Füredi, J | 1 |
| Bartko, G | 1 |
| Janka, Z | 1 |
| Banki, CM | 1 |
| Kovacs, G | 1 |
| Breier, A | 2 |
| Casey, DE | 3 |
| Tollefson, GD | 4 |
| Tran, PV | 2 |
| Street, JS | 1 |
| Krueger, JA | 1 |
| Tamura, RN | 1 |
| Graffeo, KA | 1 |
| Thieme, ME | 1 |
| Dellva, MA | 1 |
| Potvin, JH | 1 |
| Kiesler, GM | 1 |
| Nemeroff, CB | 1 |
| Sheitman, BB | 1 |
| Lindgren, JC | 1 |
| Early, J | 1 |
| Sved, M | 1 |
| Martín, J | 1 |
| García-Bernardo, E | 1 |
| Cuesta, M | 1 |
| Alvarez, E | 1 |
| Gurpegui, M | 1 |
| Allan, ER | 1 |
| Sison, CE | 1 |
| Alpert, M | 1 |
| Connolly, B | 1 |
| Crichton, J | 1 |
| Conley, RR | 3 |
| Tamminga, CA | 1 |
| Bartko, JJ | 1 |
| Richardson, C | 1 |
| Peszke, M | 1 |
| Lingle, J | 1 |
| Hegerty, J | 1 |
| Love, R | 1 |
| Gounaris, C | 1 |
| Zaremba, S | 1 |
| Graham, JM | 1 |
| Sussman, JD | 1 |
| Ford, KS | 1 |
| Sagar, HJ | 1 |
| Chambers, RA | 1 |
| Caracansi, A | 1 |
| Weiss, G | 1 |
| Sanger, TM | 1 |
| Grundy, S | 1 |
| Beasley, C | 1 |
| Leucht, S | 1 |
| Pitschel-Walz, G | 1 |
| Abraham, D | 1 |
| Kissling, W | 1 |
| Tandon, R | 1 |
| Milner, K | 1 |
| Jibson, MD | 1 |
| Timmerman, W | 1 |
| Heijmen, M | 1 |
| Westerink, BH | 1 |
| Bruggeman, R | 1 |
| den Boer, JA | 1 |
| Dresel, S | 2 |
| Mager, T | 2 |
| Rossmüller, B | 2 |
| Meisenzahl, E | 1 |
| Hahn, K | 2 |
| Möller, HJ | 2 |
| Tatsch, K | 2 |
| Rudolf, J | 1 |
| Ghaemi, M | 1 |
| Schmülling, S | 1 |
| Glazer, WM | 1 |
| Jeste, DV | 1 |
| Meltzer, HY | 2 |
| Bronson, BD | 1 |
| Kopelowicz, A | 1 |
| Zarate, R | 1 |
| Tripodis, K | 1 |
| Gonzalez, V | 1 |
| Mintz, J | 1 |
| Sacristán, JA | 2 |
| Hernández, J | 1 |
| Ruiz Carrasco, P | 1 |
| Antón Saiz, C | 1 |
| Fontova Carbonell, E | 1 |
| Montejo, AL | 1 |
| Vieta, E | 1 |
| Gregor, KJ | 1 |
| Ishigooka, J | 1 |
| Murasaki, M | 1 |
| Guille, C | 1 |
| Sachs, GS | 1 |
| Ghaemi, SN | 1 |
| Price, PL | 1 |
| Shelton, RC | 1 |
| Stahl, S | 1 |
| Gannon, KS | 1 |
| Jacobs, TG | 1 |
| Buras, WR | 1 |
| Bymaster, FP | 1 |
| Zhang, W | 1 |
| Spencer, KA | 1 |
| Damodaran, SS | 1 |
| Thankamma, JK | 1 |
| Meisenzahl, EM | 1 |
| Frodl, T | 1 |
| Schmitt, GJ | 1 |
| Preuss, UW | 1 |
| Karagianis, JL | 1 |
| Dawe, IC | 1 |
| Thakur, A | 1 |
| Bégin, S | 1 |
| Raskin, J | 1 |
| Roychowdhury, SM | 1 |
| Mahmoud, R | 1 |
| Lieberman, J | 1 |
| Parker, B | 1 |
| Iskander, A | 1 |
| Buckley, PF | 1 |
| Miller, DS | 1 |
| Yatham, LN | 1 |
| Lam, RW | 1 |
| Schillevoort, I | 1 |
| de Boer, A | 1 |
| Herings, RM | 1 |
| Roos, RA | 1 |
| Jansen, PA | 1 |
| Leufkens, HG | 1 |
| Zullino, DF | 1 |
| Delessert, D | 1 |
| Eap, CB | 1 |
| Preisig, M | 1 |
| Baumann, P | 1 |
| Kim, KS | 1 |
| Pae, CU | 1 |
| Chae, JH | 1 |
| Bahk, WM | 1 |
| Jun, TY | 1 |
| Kim, DJ | 1 |
| Dickson, RA | 1 |
14 reviews available for pirenzepine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.
Topics: Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition; Comorbi | 2003 |
Pharmacological approaches to the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant | 2003 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Dosing the antipsychotic medication olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Respons | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D | 1997 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Meth | 1999 |
Tardive dyskinesia and atypical antipsychotic drugs.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 1999 |
Antipsychotics from theory to practice: integrating clinical and basic data.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Cl | 1999 |
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brain; Clozapine; Dibenzothiazepines; | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
24 trials available for pirenzepine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; H | 2002 |
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cross-Over Studies; Double-Bli | 2002 |
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Chronic Disease; Drug Re | 2002 |
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagnosis, Differential; Femal | 2003 |
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Corpus Striatum; D | 2003 |
Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Female; Hu | 2003 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho | 2003 |
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; | 2004 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 1997 |
Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale | 1997 |
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Haloperidol; Humans; Mal | 1998 |
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; | 1998 |
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Response Relationship, Dru | 1998 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin | 1999 |
Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cross-Sectional Studies; Drug | 2000 |
Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.
Topics: Adult; Age of Onset; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; | 2000 |
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepi | 2000 |
Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric | 2000 |
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Body Weight; | 2000 |
A novel augmentation strategy for treating resistant major depression.
Topics: Ambulatory Care; Basal Ganglia Diseases; Benzodiazepines; Depressive Disorder; Double-Blind Method; | 2001 |
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Brain; Brain Chemi | 2000 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female | 2002 |
18 other studies available for pirenzepine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Effects of development on olanzapine-associated adverse events.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Antipsychotic Agents; Basal | 2002 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
High-dose olanzapine for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chronic Disease; Drug Administ | 1997 |
Olanzapine overdose cause of acute extrapyramidal symptoms.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Drug Overdose; | 1998 |
Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Haloperidol; Male | 1999 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studi | 1999 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine | 1999 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance. Dallas, Texas, California. January 22, 1999. Proceedings of a roundtable.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzoth | 2000 |
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Corpus | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilizat | 2000 |
Olanzapine to treat the acute mania of bipolar disorder.
Topics: Acute Disease; Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disord | 2000 |
Reversal of rabbit syndrome with olanzapine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; M | 2000 |
Rapid tranquilization with olanzapine in acute psychosis: a case series.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Administration Sc | 2001 |
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Resistance; Female; Human | 2001 |
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepine | 2001 |
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepin | 2001 |
Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Confusion; Cytochro | 2002 |